ReviewBioengineering (Basel, Switzerland)2022
Recent Advances in Phage-Based Therapeutics for Multi-Drug Resistant
Review in Bioengineering (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-ResistantPharmaceutics · 2026Review
- Synergistic effects of halo-plaque forming phage cocktails against polymicrobialMicrobiology spectrum · 2026Article
- AUBFM01 Phage as a Therapeutic Candidate Against MDRMicroorganisms · 2026Article
- Evaluation of three rapid antimicrobial susceptibility testing methods directly from positive blood cultures integrated with rapid pathogen identification.BMC microbiology · 2026Article
- Characterization of phage AbpL with a terminally redundant genome and its therapeutic potential against drug-resistantFrontiers in cellular and infection microbiology · 2026Article
- Bacteriophage therapy beyond antibiotics: emerging innovations for infectious and non-infectious diseases.Frontiers in cellular and infection microbiology · 2026Review
- A bacteriophage genus infects carbapenem resistantiScience · 2025Article
- Genomic and functional characterization of a novel lytic phage vB-AbaM-fThrA with anti-biofilm activity against CR-MDR Acinetobacter baumannii.BMC microbiology · 2025Article
- Phage to ESKAPE: Personalizing Therapy for MDR Infections-A Comprehensive Clinical Review.Pathogens (Basel, Switzerland) · 2025Review
- Genomic characterization and pre-clinical evaluation of a new polyvalent lytic Loughborough phage.Applied microbiology and biotechnology · 2025Article
- In vitro, genomic characterization and pre-clinical evaluation of a new thermostable lytic Obolenskvirus phage formulated as a hydrogel against carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2025Article
- Characterization of a novel lytic phage vB_AbaM_AB4P2 encoding depolymerase and its application in eliminating biofilms formed by Acinetobacter baumannii.BMC microbiology · 2025Article
- Discovery, structural characteristics and evolutionary analyses of functional domains in Acinetobacter baumannii phage tail fiber/spike proteins.BMC microbiology · 2025Article
- Article
- Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections.Frontiers in pharmacology · 2025Article
- Guava Leaf Extract Exhibits Antimicrobial Activity in Extensively Drug-Resistant (XDR)Molecules (Basel, Switzerland) · 2024Article
- A review of the fighting Acinetobacter baumannii on three fronts: antibiotics, phages, and nanoparticles.Molecular biology reports · 2024Review
- Reversing the Natural Drug Resistance of Gram-Negative Bacteria to Fusidic Acid via Forming Drug-Phospholipid Complex.Bioengineering (Basel, Switzerland) · 2024Article
- NewInternational journal of molecular sciences · 2024Article
- Characterization of bacteriophage vB_AbaS_SA1 and its synergistic effects with antibiotics against clinical multidrug-resistant Acinetobacter baumannii isolates.Pathogens and disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.